BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, January 20, 2026
See today's BioWorld
Home
» Capital Royalty's $805M Fund: Sifting Through Surplus of Deals
To read the full story,
subscribe
or
sign in
.
Capital Royalty's $805M Fund: Sifting Through Surplus of Deals
May 3, 2013
By
Randy Osborne
Risk-shy investors who'd rather bank on approved products make up Capital Royalty L.P.'s second fund, $805 million worth of private equity for betting in increments of between $20 million and $200 million, though the amounts could go higher.
BioWorld